schliessen

Filtern

 

Bibliotheken

Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial

The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular DiseasePreterax and Diamicron Controlled Evaluati... Full description

Journal Title: Hypertension (Dallas Tex. 1979), 2014, Vol.63 (2), p.259-264
Main Author: Chalmers, John
Other Authors: Arima, Hisatomi , Woodward, Mark , Mancia, Giuseppe , Poulter, Neil , Hirakawa, Yoichiro , Zoungas, Sophia , Patel, Anushka , Williams, Bryan , Harrap, Stephen
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Hagerstown, MD: American Heart Association, Inc
ID: ISSN: 0194-911X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_crossref_primary_10_1161_HYPERTENSIONAHA_113_02252
title: Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
format: Article
creator:
  • Chalmers, John
  • Arima, Hisatomi
  • Woodward, Mark
  • Mancia, Giuseppe
  • Poulter, Neil
  • Hirakawa, Yoichiro
  • Zoungas, Sophia
  • Patel, Anushka
  • Williams, Bryan
  • Harrap, Stephen
subjects:
  • Adult
  • Aged
  • Antihypertensive Agents - administration & dosage
  • Antihypertensive Agents - adverse effects
  • Arterial hypertension. Arterial hypotension
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Blood Pressure - drug effects
  • Calcium Channel Blockers - administration & dosage
  • Calcium Channel Blockers - adverse effects
  • Cardiology. Vascular system
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes Mellitus, Type 2 - mortality
  • Diabetes. Impaired glucose tolerance
  • Dihydropyridines - administration & dosage
  • Dihydropyridines - adverse effects
  • Drug Combinations
  • Drug Therapy, Combination
  • Endocrine pancreas. Apud cells (diseases)
  • Endocrinopathies
  • Etiopathogenesis. Screening. Investigations. Target tissue resistance
  • Female
  • Gliclazide - administration & dosage
  • Gliclazide - adverse effects
  • Humans
  • Hypertension - drug therapy
  • Hypertension - mortality
  • Hypoglycemic Agents - administration & dosage
  • Hypoglycemic Agents - adverse effects
  • Indapamide - administration & dosage
  • Indapamide - adverse effects
  • Male
  • Medical sciences
  • Middle Aged
  • Perindopril - administration & dosage
  • Perindopril - adverse effects
  • Proportional Hazards Models
ispartof: Hypertension (Dallas, Tex. 1979), 2014, Vol.63 (2), p.259-264
description: The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular DiseasePreterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril–indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%–43%) among patients with CCB at baseline compared with 5% (−12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%–25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (−8% to 28%) versus 6% (−10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.
language: eng
source:
identifier: ISSN: 0194-911X
fulltext: no_fulltext
issn:
  • 0194-911X
  • 1524-4563
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6200535
LOCALfalse
PrimoNMBib
record
control
sourceidpubmed_cross
recordidTN_cdi_crossref_primary_10_1161_HYPERTENSIONAHA_113_02252
sourceformatXML
sourcesystemPC
sourcerecordid24324048
originalsourceidFETCH-LOGICAL-13922-cce67925456e62d242ccf52b1b2cc339ae90c6b32117e92eacdb5a22a0e903180
addsrcrecordideNqNUdFu0zAUtRCIlcEvIPOABNIyYsdJm0k8hCyjlUZXjTLgKbpxbhRvjlPZCWOfzR_gtmNIPPFk-95zzr0-h5BXLDxmLGHv5t9XxeW6WH5eXCyzeeaL0XHIecwfkQmLuQhEnESPySRkqQhSxr4dkGfOXYchE0JMn5IDLiIuQjGbkF9F06AcHO0bmvddpQwMqjfb5wqtMnW_sUof0YWpYQOdqvGIgqlpDlqqsaN5C8agph90L2_QOqoMXXkJNF7zqxpaur7bIOX0VEGFAzr6CbVWw-hO6CW6UXvYme07OrRIM7mb7SUe0NtZV-DkqMH6qkNweEJX1jct_Ny1PbZT0npi3pvB9lpjTYsfoMf9V95kp1fZMi_e0rVVoJ-TJw1ohy_uz0Py5axY5_Pg_OLjIs_OAxalnAdSYjJNeeytxITXXHApm5hXrPKXKEoB01AmVcQZm2LKEWRdxcA5hL4RsVl4SNK9rl_NOYtN6Z3swN6VLCy3MZb_xOiLUbmL0XNf7rmbseqwfmD-yc0DXt8DvDegGwtGKvcXN2PJLEmZx73f42577R1zN3q8RVu2CHpo_2OR3_-qvlU
sourcetypeAggregation Database
isCDItrue
recordtypearticle
display
typearticle
titleEffects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
creatorChalmers, John ; Arima, Hisatomi ; Woodward, Mark ; Mancia, Giuseppe ; Poulter, Neil ; Hirakawa, Yoichiro ; Zoungas, Sophia ; Patel, Anushka ; Williams, Bryan ; Harrap, Stephen
creatorcontribChalmers, John ; Arima, Hisatomi ; Woodward, Mark ; Mancia, Giuseppe ; Poulter, Neil ; Hirakawa, Yoichiro ; Zoungas, Sophia ; Patel, Anushka ; Williams, Bryan ; Harrap, Stephen
descriptionThe objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular DiseasePreterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril–indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%–43%) among patients with CCB at baseline compared with 5% (−12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%–25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (−8% to 28%) versus 6% (−10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.
identifier
0ISSN: 0194-911X
1EISSN: 1524-4563
2DOI: 10.1161/HYPERTENSIONAHA.113.02252
3PMID: 24324048
4CODEN: HPRTDN
languageeng
publisherHagerstown, MD: American Heart Association, Inc
subject
ispartofHypertension (Dallas, Tex. 1979), 2014, Vol.63 (2), p.259-264
rights
02014 American Heart Association, Inc
12015 INIST-CNRS
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-13922-cce67925456e62d242ccf52b1b2cc339ae90c6b32117e92eacdb5a22a0e903180
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28168691$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24324048$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Chalmers, John
1Arima, Hisatomi
2Woodward, Mark
3Mancia, Giuseppe
4Poulter, Neil
5Hirakawa, Yoichiro
6Zoungas, Sophia
7Patel, Anushka
8Williams, Bryan
9Harrap, Stephen
title
0Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
1Hypertension (Dallas, Tex. 1979)
addtitleHypertension
descriptionThe objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular DiseasePreterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril–indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%–43%) among patients with CCB at baseline compared with 5% (−12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%–25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (−8% to 28%) versus 6% (−10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.
subject
0Adult
1Aged
2Antihypertensive Agents - administration & dosage
3Antihypertensive Agents - adverse effects
4Arterial hypertension. Arterial hypotension
5Biological and medical sciences
6Blood and lymphatic vessels
7Blood Pressure - drug effects
8Calcium Channel Blockers - administration & dosage
9Calcium Channel Blockers - adverse effects
10Cardiology. Vascular system
11Diabetes Mellitus, Type 2 - drug therapy
12Diabetes Mellitus, Type 2 - mortality
13Diabetes. Impaired glucose tolerance
14Dihydropyridines - administration & dosage
15Dihydropyridines - adverse effects
16Drug Combinations
17Drug Therapy, Combination
18Endocrine pancreas. Apud cells (diseases)
19Endocrinopathies
20Etiopathogenesis. Screening. Investigations. Target tissue resistance
21Female
22Gliclazide - administration & dosage
23Gliclazide - adverse effects
24Humans
25Hypertension - drug therapy
26Hypertension - mortality
27Hypoglycemic Agents - administration & dosage
28Hypoglycemic Agents - adverse effects
29Indapamide - administration & dosage
30Indapamide - adverse effects
31Male
32Medical sciences
33Middle Aged
34Perindopril - administration & dosage
35Perindopril - adverse effects
36Proportional Hazards Models
issn
00194-911X
11524-4563
fulltextfalse
rsrctypearticle
creationdate2014
recordtypearticle
recordideNqNUdFu0zAUtRCIlcEvIPOABNIyYsdJm0k8hCyjlUZXjTLgKbpxbhRvjlPZCWOfzR_gtmNIPPFk-95zzr0-h5BXLDxmLGHv5t9XxeW6WH5eXCyzeeaL0XHIecwfkQmLuQhEnESPySRkqQhSxr4dkGfOXYchE0JMn5IDLiIuQjGbkF9F06AcHO0bmvddpQwMqjfb5wqtMnW_sUof0YWpYQOdqvGIgqlpDlqqsaN5C8agph90L2_QOqoMXXkJNF7zqxpaur7bIOX0VEGFAzr6CbVWw-hO6CW6UXvYme07OrRIM7mb7SUe0NtZV-DkqMH6qkNweEJX1jct_Ny1PbZT0npi3pvB9lpjTYsfoMf9V95kp1fZMi_e0rVVoJ-TJw1ohy_uz0Py5axY5_Pg_OLjIs_OAxalnAdSYjJNeeytxITXXHApm5hXrPKXKEoB01AmVcQZm2LKEWRdxcA5hL4RsVl4SNK9rl_NOYtN6Z3swN6VLCy3MZb_xOiLUbmL0XNf7rmbseqwfmD-yc0DXt8DvDegGwtGKvcXN2PJLEmZx73f42577R1zN3q8RVu2CHpo_2OR3_-qvlU
startdate201402
enddate201402
creator
0Chalmers, John
1Arima, Hisatomi
2Woodward, Mark
3Mancia, Giuseppe
4Poulter, Neil
5Hirakawa, Yoichiro
6Zoungas, Sophia
7Patel, Anushka
8Williams, Bryan
9Harrap, Stephen
general
0American Heart Association, Inc
1Lippincott Williams & Wilkins
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
sort
creationdate201402
titleEffects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
authorChalmers, John ; Arima, Hisatomi ; Woodward, Mark ; Mancia, Giuseppe ; Poulter, Neil ; Hirakawa, Yoichiro ; Zoungas, Sophia ; Patel, Anushka ; Williams, Bryan ; Harrap, Stephen
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-13922-cce67925456e62d242ccf52b1b2cc339ae90c6b32117e92eacdb5a22a0e903180
rsrctypearticles
prefilterarticles
languageeng
creationdate2014
topic
0Adult
1Aged
2Antihypertensive Agents - administration & dosage
3Antihypertensive Agents - adverse effects
4Arterial hypertension. Arterial hypotension
5Biological and medical sciences
6Blood and lymphatic vessels
7Blood Pressure - drug effects
8Calcium Channel Blockers - administration & dosage
9Calcium Channel Blockers - adverse effects
10Cardiology. Vascular system
11Diabetes Mellitus, Type 2 - drug therapy
12Diabetes Mellitus, Type 2 - mortality
13Diabetes. Impaired glucose tolerance
14Dihydropyridines - administration & dosage
15Dihydropyridines - adverse effects
16Drug Combinations
17Drug Therapy, Combination
18Endocrine pancreas. Apud cells (diseases)
19Endocrinopathies
20Etiopathogenesis. Screening. Investigations. Target tissue resistance
21Female
22Gliclazide - administration & dosage
23Gliclazide - adverse effects
24Humans
25Hypertension - drug therapy
26Hypertension - mortality
27Hypoglycemic Agents - administration & dosage
28Hypoglycemic Agents - adverse effects
29Indapamide - administration & dosage
30Indapamide - adverse effects
31Male
32Medical sciences
33Middle Aged
34Perindopril - administration & dosage
35Perindopril - adverse effects
36Proportional Hazards Models
toplevelpeer_reviewed
creatorcontrib
0Chalmers, John
1Arima, Hisatomi
2Woodward, Mark
3Mancia, Giuseppe
4Poulter, Neil
5Hirakawa, Yoichiro
6Zoungas, Sophia
7Patel, Anushka
8Williams, Bryan
9Harrap, Stephen
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
jtitleHypertension (Dallas, Tex. 1979)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Chalmers, John
1Arima, Hisatomi
2Woodward, Mark
3Mancia, Giuseppe
4Poulter, Neil
5Hirakawa, Yoichiro
6Zoungas, Sophia
7Patel, Anushka
8Williams, Bryan
9Harrap, Stephen
formatjournal
genrearticle
ristypeJOUR
atitleEffects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
jtitleHypertension (Dallas, Tex. 1979)
addtitleHypertension
date2014-02
risdate2014
volume63
issue2
spage259
epage264
pages259-264
issn0194-911X
eissn1524-4563
codenHPRTDN
abstractThe objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular DiseasePreterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril–indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%–43%) among patients with CCB at baseline compared with 5% (−12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%–25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (−8% to 28%) versus 6% (−10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.
copHagerstown, MD
pubAmerican Heart Association, Inc
pmid24324048
doi10.1161/HYPERTENSIONAHA.113.02252
oafree_for_read